<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02685605</url>
  </required_header>
  <id_info>
    <org_study_id>INTRAGO-II</org_study_id>
    <secondary_id>ARO-2016-1</secondary_id>
    <nct_id>NCT02685605</nct_id>
  </id_info>
  <brief_title>Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme</brief_title>
  <acronym>INTRAGO-II</acronym>
  <official_title>A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsmedizin Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Carl Zeiss Meditec AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsmedizin Mannheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      INTRAGO II resembles a multicentric, prospective, randomized, 2-arm, open-label clinical
      phase III trial which tests if the median progression-free survival (PFS) of patients with
      newly diagnosed glioblastoma multiforme (GBM) can be improved by the addition of
      intraoperative radiotherapy (IORT) to standard radiochemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2016</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Progression-Free Survival</measure>
    <time_frame>24 Months</time_frame>
    <description>Determined according to modified Response Assessment in Neuro-Oncology (RANO) criteria and serial perfusion imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS within a 1-2 cm margin around the cavity</measure>
    <time_frame>24 Months</time_frame>
    <description>Determined by serial contrast-enhanced MRI scans using modified RANO criteria and serial perfusion imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS with respect to Age</measure>
    <time_frame>24 Months</time_frame>
    <description>Median overall survival of patients &lt;65 vs. ≥ 65 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS with respect to Age</measure>
    <time_frame>24 Months</time_frame>
    <description>Progression-free survival of patients &lt;65 vs. ≥ 65 years; determined according to modified RANO criteria and serial perfusion imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS with respect to KPS</measure>
    <time_frame>24 Months</time_frame>
    <description>Median overall survival of patients with KPS 80-100% vs. 60-70%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS with respect to KPS</measure>
    <time_frame>24 Months</time_frame>
    <description>Progression-free survival of patients with KPS 80-100% vs. 60-70%; determined according to modified RANO criteria and serial perfusion imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS with respect to thickness of anticipated T1-Gd-enhancing (remaining) tumor margin</measure>
    <time_frame>24 Months</time_frame>
    <description>Thickness of anticipated T1-Gd-enhancing (remaining) tumor margin as per the discretion of the surgeon (margin ≥0.5 cm or multiple spots of residual tumor within the cavity vs. &lt;0.5 cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS with respect to thickness of anticipated T1-Gd-enhancing (remaining) tumor margin</measure>
    <time_frame>24 Months</time_frame>
    <description>Thickness of anticipated T1-Gd-enhancing (remaining) tumor margin as per the discretion of the surgeon (margin ≥0.5 cm or multiple spots of residual tumor within the cavity vs. &lt;0.5 cm); determined according to modified RANO criteria and serial perfusion imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS with respect to extent of resection</measure>
    <time_frame>24 Months</time_frame>
    <description>Early postoperative MRI scans must be used to determine the extent of resection (EoR). The EoR is given as sum of all maximum diameters of residual lesions in cm. OS will be calculated for the following groups:
Max Diameter group 0: 0 cm (no residual tumor)
Max Diameter group 1: &gt;0 to ≤1.5 cm (cumulative if multiple residual lesions)
Max Diameter group 2: &gt;1.5 cm (cumulative if multiple residual lesions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS with respect to extent of resection</measure>
    <time_frame>24 Months</time_frame>
    <description>Early postoperative MRI scans must be used to determine the extent of resection (EoR). The EoR is given as sum of all maximum diameters of residual lesions in cm. PFS will be determined according to modified RANO criteria and serial perfusion imaging for the following groups:
Max Diameter group 0: 0 cm (no residual tumor)
Max Diameter group 1: &gt;0 to ≤1.5 cm (cumulative if multiple residual lesions)
Max Diameter group 2: &gt;1.5 cm (cumulative if multiple residual lesions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS with respect to MGMT promoter methylation status</measure>
    <time_frame>24 Months</time_frame>
    <description>OS in patients with promoter methylation vs. no promoter methylation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS with respect to MGMT promoter methylation status</measure>
    <time_frame>24 Months</time_frame>
    <description>PFS in patients with promoter methylation vs. no promoter methylation; determined according to modified RANO criteria and serial perfusion imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL) questionnaire</measure>
    <time_frame>24 Months</time_frame>
    <description>Assessed by European Organization for Research and Treatment (EORTC)- Quality of Life Questionnaires (QLQ C30/BN20)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of daily living (ADL), assessed using the Barthel Index (Mahoney &amp; Barthel, 1965).</measure>
    <time_frame>24 Months</time_frame>
    <description>Change in functional outcomes as measured by BI from its baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation-related (acute / early delayed / late) neurotoxicity</measure>
    <time_frame>24 Months</time_frame>
    <description>Assessed by regular neurological examinations and serial MRI scans</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">314</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Experimental Arm (A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard surgery plus intraoperative radiotherapy (20-30 Gy) followed by radiochemotherapy (EBRT: 60 Gy, 75 mg/m2/d temozolomide) and adjuvant chemotherapy with 150-200 mg/m2/d temozolomide per cycle (5/28 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm (B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard surgery followed by radiochemotherapy (EBRT: 60 Gy, 75 mg/m2/d temozolomide) and adjuvant chemotherapy with 150-200 mg/m2/d temozolomide per cycle (5/28 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard surgery (neuronavigation-guided)</intervention_name>
    <arm_group_label>Control Arm (B)</arm_group_label>
    <arm_group_label>Experimental Arm (A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intraoperative radiotherapy</intervention_name>
    <description>Dose to applicator surface: 20-30 Gy; Carl Zeiss INTRABEAM System. IORT with a surface dose of 30 Gy is recommended.Should the proximity to any risk structure not allow to apply 30 Gy, a dose reduction by up to 10 Gy (resulting in a surface dose of 20 Gy) is allowed.</description>
    <arm_group_label>Experimental Arm (A)</arm_group_label>
    <other_name>IORT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiochemotherapy</intervention_name>
    <description>EBRT to 60 Gy plus 75 mg/m2/d temozolomide</description>
    <arm_group_label>Control Arm (B)</arm_group_label>
    <arm_group_label>Experimental Arm (A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Adjuvant chemotherapy with 150-200 mg/m2/d temozolomide per cycle (5/28 days).</description>
    <arm_group_label>Control Arm (B)</arm_group_label>
    <arm_group_label>Experimental Arm (A)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Age ≥18 and ≤ 80 years

          2. Karnofsky Performance Score (KPS) ≥ 60%

          3. Supratentorial T1-Gd enhancing lesion(s) amenable to total resection

          4. Legal capacity and ability of subject to understand character and individual
             consequences of the clinical trial

          5. Patient's written IC obtained at least 24h prior to surgery

          6. For women with childbearing potential: adequate contraception

          7. Patients must have adequate organ functions

             Bone marrow function:

               -  Platelets ≥ 75.000/μL

               -  WBC ≥ 3.000/μL

               -  Hemoglobin ≥ 10.0 g/dL

             Liver Function:

               -  ASAT and ALAT ≤ 3.0 times ULN

               -  ALP ≤ 2.5 times ULN

               -  Total Serum Bilirubin &lt; 1.5 times ULN

             Renal Function:

               -  Serum Creatinine ≤ 1.5 times ULN

             Inclusion Criteria Related to Surgery:

          8. IORT must be technically feasible

          9. Histology supports diagnosis of GBM

        Exclusion Criteria

          1. Multicentric disease (e.g. in both hemispheres) or non-resectable satellite lesions

          2. Previous cranial radiation therapy

          3. Cytostatic therapy / chemotherapy for cancer within the past 5 years

          4. History of cancers or other comorbidities that limit life expectancy to less than five
             years

          5. Previous therapy with anti-angiogenic substances (such as bevacizumab)

          6. Technical impossibility to use MRI or known allergies against MRI and/or CT contrast
             agents

          7. Participation in other clinical trials testing cancer-derived investigational
             agents/procedures.

          8. Pregnant or breast feeding patients

          9. Fertile patients refusing to use safe contraceptive methods during the study

             Exclusion Criteria Related to Surgery:

         10. Active egress of fluids from a ventricular defect

         11. In-field risk organs and/or IORT dose &gt;8 Gy to any risk organ
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank A. Giordano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiation Oncology, University Hospital Bonn, Univeristy of Bonn, Bonn, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin Petrecca, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurosurgery, Montréal Neurological, Institute and Hospital, Montréal, Canada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elena Sperk</last_name>
    <phone>+49621383</phone>
    <phone_ext>6020</phone_ext>
    <email>studien.strahlen@medma.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anette Kipke</last_name>
    <phone>+49621383</phone>
    <phone_ext>6020</phone_ext>
    <email>studien.strahlen@medma.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Barrow Neurological Institute (SJHMC)</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rima Woo</last_name>
      <email>Rima.Woo@barrowbrainandspine.com</email>
    </contact>
    <investigator>
      <last_name>Peter Nakaji, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stritch School of Medicine Loyola University</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth A Chiappetta, RN, BSN, CCRP</last_name>
      <phone>708-216</phone>
      <phone_ext>2568</phone_ext>
      <email>BCHIAPPETTA@lumc.edu</email>
    </contact>
    <investigator>
      <last_name>Abhishek Solanki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center, North Shore University Hospital</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise A Purcell, MS ANP-C CCRN-CMC</last_name>
      <phone>+1 516-941</phone>
      <phone_ext>1263</phone_ext>
      <email>LPurcell@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Schulder, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lenox Hill Hospital, Hofstra Northwell School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamika A Wong, MPH</last_name>
      <phone>212-434-4836</phone>
      <email>twong4@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>John A. Boockvar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506-9260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Brunetti</last_name>
      <phone>304-293-7360</phone>
    </contact>
    <investigator>
      <last_name>Christopher P Cifarelli, MD, PhD, FAANS, FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute and Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Pietromonaco</last_name>
      <phone>+1-514-398-</phone>
      <phone_ext>2591</phone_ext>
      <email>anna.pietromonaco@mcgill.ca</email>
    </contact>
    <contact_backup>
      <last_name>Gregory Ringkamp</last_name>
      <phone>+1-514-398-</phone>
      <phone_ext>2667</phone_ext>
      <email>gregory.ringkamp@mcgill.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Kevin Petrecca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis Souhami, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Schill, PhD</last_name>
      <phone>+49 821 400 25 42</phone>
      <email>Sabine.Schill@klinikum-augsburg.de</email>
    </contact>
    <investigator>
      <last_name>Klaus H Kahl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Georg</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Sorge, MD</last_name>
      <email>Oliver.Sorge@sanktgeorg.de</email>
    </contact>
    <contact_backup>
      <last_name>Anna Hedwig Müller</last_name>
      <email>Anna-Hedwig.Mueller@SanktGeorg.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anke Keller, MSc</last_name>
      <phone>00496213834960</phone>
      <email>anke.keller@medma.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Frank A Giordano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Haenggi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Platten, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Technical University of Munich (TUM), Department of Radiation Oncology</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Kessel, PhD</last_name>
      <phone>+49 89 4140-4501</phone>
      <email>carmen.kessel@tum.de]</email>
    </contact>
    <investigator>
      <last_name>Stephanie E Combs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Arzbach</last_name>
      <phone>+49 711/ 278-33700</phone>
      <email>u.arzbach@klinikum-stuttgart.de</email>
    </contact>
    <investigator>
      <last_name>Oliver Ganslandt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Münter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catalan Institute of Oncology (ICO)</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Montserrat Ventura Bujalance</last_name>
      <phone>+ 34 93 260 77 22</phone>
      <email>montseventura@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Ferran Guedea, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Garcia Cabezas, MD</last_name>
      <email>songar1@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Juan Solivera Vela, MD</last_name>
      <email>juan.solivera@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The London Clinic</name>
      <address>
        <city>London</city>
        <zip>W1G 6BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine Topham</last_name>
      <phone>020 3219 3570</phone>
      <phone_ext>8389</phone_ext>
      <email>C.Topham@thelondonclinic.co.uk</email>
    </contact>
    <contact_backup>
      <last_name>Alistair Gifford-Moore</last_name>
      <phone>020 3219 3570</phone>
      <phone_ext>8384</phone_ext>
      <email>A.Gifford-Moore@thelondonclinic.co.uk</email>
    </contact_backup>
    <investigator>
      <last_name>n.n. n.n.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Giordano FA, Wenz F, Petrecca K. Rationale for intraoperative radiotherapy in glioblastoma. J Neurosurg Sci. 2016 Sep;60(3):350-6. Epub 2016 Jan 29. Review.</citation>
    <PMID>26824195</PMID>
  </reference>
  <reference>
    <citation>Giordano FA, Brehmer S, Abo-Madyan Y, Welzel G, Sperk E, Keller A, Schneider F, Clausen S, Herskind C, Schmiedek P, Wenz F. INTRAGO: intraoperative radiotherapy in glioblastoma multiforme—a phase I/II dose escalation study. BMC Cancer. 2014 Dec 22;14:992. doi: 10.1186/1471-2407-14-992.</citation>
    <PMID>25535398</PMID>
  </reference>
  <reference>
    <citation>Giordano FA, Abo-Madyan Y, Brehmer S, Herskind C, Sperk E, Schneider F, Clausen S, Welzel G, Schmiedek P, Wenz F. Intraoperative radiotherapy (IORT)—a resurrected option for treating glioblastoma? Transl Cancer Res 2014 Jan 14. doi: 10.3978/j.issn.2218-676X.2014.01.03</citation>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 5, 2016</study_first_submitted>
  <study_first_submitted_qc>February 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2016</study_first_posted>
  <last_update_submitted>May 3, 2020</last_update_submitted>
  <last_update_submitted_qc>May 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Frank A. Giordano</investigator_full_name>
    <investigator_title>PI (Chair)</investigator_title>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <keyword>Intraoperative Radiotherapy</keyword>
  <keyword>Radiotherapy Dose Escalation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

